Dr. Andrews Hill’s Ivermectin meta-analysis, from University of Liverpool, England, supported by The Access to COVID-19 Tools (ACT) Accelerator. Presentation from MedinCell Workshop (16 December).
“In conclusion, in this meta-analysis we are seeing using standard WHO grade criteria a faster time to viral clearance, a shorter duration of hospitalisation, 43% higher rates of clinical recovery [1] and 83% improvement in survival rates [2],” said Dr Hill.
[1] 95% C.I. 21-67%
[2] 95% C.I 65-92%